File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Dendritic cell (DC) enhances VEGF clearance from neuroblastoma - a mechanism for DC-based immunotherapy

TitleDendritic cell (DC) enhances VEGF clearance from neuroblastoma - a mechanism for DC-based immunotherapy
Authors
Issue Date2006
Citation
AACR 97th Annual Meeting, Washington, DC, 1–5 April 2006. In Cancer Research, 2006, v. 66 n. 8S, p. 1745 Abstract no. 3163 How to Cite?
AbstractAim of the Study: Vascular endothelial growth factor (VEGF) is up-regulated in a number of tumor types including neuroblastoma. It has been reported that VEGF expression is inversely correlated with dendritic cells (DCs) infiltration in tumor specimens. Furthermore, the plasma levels of VEGF in tumor patients decreased during DC-based immunotherapy. Therefore, our hypothesis is whether DCs have a capacity to clear VEGF. Methods: Monocyte-derived DCs were co-cultured with supernatants from neuroblastoma cell culture containing large amount of VEGF (tumor conditioned medium, TCM) and recombinant human VEGF (rh VEGF), respectively. The concentrations of VEGF in the supernatants, the intracellular VEGF in DCs and the VEGF mRNA level of DCs were detected by ELISA, FACS and Q-PCR, respectively. Results: When DCs were co-cultured with TCM or rhVEGF for 3 hours, the levels of VEGF in the supernatants were significantly decreased, while the intracellular VEGF in DCs was increased. In addition, exogenous rhVEGF did not increase VEGF mRNA expression in DCs, suggesting that increased VEGF levels in DCs was due to up-take VEGF from supernatants. The function of DCs to take up VEGF could be abolished by pretreatment DCs with neutralizing antibody against VEGF receptor 1. Conclusion: It is the first time to show the novel function of DCs. Our results suggested that DCs might exert anti-angiogenic effect by clearance of VEGF via VEGF receptor 1. Therefore, administration of DCs may be the potential therapeutic strategy for patients with neuroblastoma.
Persistent Identifierhttp://hdl.handle.net/10722/108072
ISSN
2015 Impact Factor: 8.556
2015 SCImago Journal Rankings: 5.372

 

DC FieldValueLanguage
dc.contributor.authorRen, Yen_HK
dc.contributor.authorXie, Yen_HK
dc.contributor.authorTam, PKHen_HK
dc.date.accessioned2010-09-26T00:24:17Z-
dc.date.available2010-09-26T00:24:17Z-
dc.date.issued2006en_HK
dc.identifier.citationAACR 97th Annual Meeting, Washington, DC, 1–5 April 2006. In Cancer Research, 2006, v. 66 n. 8S, p. 1745 Abstract no. 3163-
dc.identifier.issn0008-5472-
dc.identifier.urihttp://hdl.handle.net/10722/108072-
dc.description.abstractAim of the Study: Vascular endothelial growth factor (VEGF) is up-regulated in a number of tumor types including neuroblastoma. It has been reported that VEGF expression is inversely correlated with dendritic cells (DCs) infiltration in tumor specimens. Furthermore, the plasma levels of VEGF in tumor patients decreased during DC-based immunotherapy. Therefore, our hypothesis is whether DCs have a capacity to clear VEGF. Methods: Monocyte-derived DCs were co-cultured with supernatants from neuroblastoma cell culture containing large amount of VEGF (tumor conditioned medium, TCM) and recombinant human VEGF (rh VEGF), respectively. The concentrations of VEGF in the supernatants, the intracellular VEGF in DCs and the VEGF mRNA level of DCs were detected by ELISA, FACS and Q-PCR, respectively. Results: When DCs were co-cultured with TCM or rhVEGF for 3 hours, the levels of VEGF in the supernatants were significantly decreased, while the intracellular VEGF in DCs was increased. In addition, exogenous rhVEGF did not increase VEGF mRNA expression in DCs, suggesting that increased VEGF levels in DCs was due to up-take VEGF from supernatants. The function of DCs to take up VEGF could be abolished by pretreatment DCs with neutralizing antibody against VEGF receptor 1. Conclusion: It is the first time to show the novel function of DCs. Our results suggested that DCs might exert anti-angiogenic effect by clearance of VEGF via VEGF receptor 1. Therefore, administration of DCs may be the potential therapeutic strategy for patients with neuroblastoma.-
dc.languageengen_HK
dc.relation.ispartofCancer Researchen_HK
dc.titleDendritic cell (DC) enhances VEGF clearance from neuroblastoma - a mechanism for DC-based immunotherapyen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailRen, Y: yren@hkucc.hku.hken_HK
dc.identifier.emailTam, PKH: paultam@hkucc.hku.hken_HK
dc.identifier.authorityTam, PKH=rp00060en_HK
dc.identifier.hkuros116370en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats